» Articles » PMID: 21081841

A Single-chain Triplebody with Specificity for CD19 and CD33 Mediates Effective Lysis of Mixed Lineage Leukemia Cells by Dual Targeting

Overview
Journal MAbs
Date 2010 Nov 18
PMID 21081841
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

A single-chain triplebody (sctb) 33-ds16-ds19 comprising two distal single-chain Fv fragments (scFvs) specific for the lymphoid antigen CD19 and the myeloid antigen CD33 flanking a central scFv specific for CD16, which is the low affinity Fc-receptor (FcγRIII) present on natural killer cells and macrophages, was produced and its properties were investigated. CD33 and CD19 in combination are present on acute leukemiablasts with mixed lineage phenotype, but not on normal human hematopoietic cells. For comparison, two bispecific scFvs (bsscFvs), ds19-ds16 and 33-ds16, with monovalent binding to CD19 and CD33, respectively, were also studied. The sctb 33-ds16-ds19 specifically interacted with all 3 antigens. On the antigen double-positive cell line BV-173, the sctb bound with 2-fold greater avidity than bsscFv ds19-ds16 (KD = 21 vs. 42 nM) and with 1.4-fold greater avidity than bsscFv 33-ds16 (KD = 29 nM). All 3 fusion proteins had similar affinity for CD16 and sufficient thermic stability in human serum. In antibody-dependent cellular cytotoxicity (ADCC) reactions with human mononuclear cells as effectors, the sctb promoted lysis of BV-173 cells at 23-fold lower concentrations than bsscFv ds19-ds16 and at 1.4-fold lower concentrations than bsscFv 33-ds16. The sctb also mediated potent ADCC of the antigen double-positive mixed lineage leukemia cell line SEM, and the half-maximal concentration EC50 for BV-173 cells was 7 pM. Therefore, CD19 and CD33 are present on the surface of these leukemic cell lines such that they can be connected by a single sctb molecule, permitting the recruitment of NK cells via CD16 and tumor cell lysis.

Citing Articles

Potent Apoptosis Induction by a Novel Trispecific B7-H3xCD16xTIGIT 2+1 Common Light Chain Natural Killer Cell Engager.

Ulitzka M, Harwardt J, Lipinski B, Tran H, Hock B, Kolmar H Molecules. 2024; 29(5).

PMID: 38474651 PMC: 10935230. DOI: 10.3390/molecules29051140.


When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy.

Tapia-Galisteo A, Compte M, Alvarez-Vallina L, Sanz L Theranostics. 2023; 13(3):1028-1041.

PMID: 36793863 PMC: 9925307. DOI: 10.7150/thno.81494.


Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer.

Tapia-Galisteo A, Sanchez Rodriguez I, Aguilar-Sopena O, Harwood S, Narbona J, Ferreras Gutierrez M Oncoimmunology. 2022; 11(1):2034355.

PMID: 35154908 PMC: 8837253. DOI: 10.1080/2162402X.2022.2034355.


Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future.

Lamb M, Rangarajan H, Tullius B, Lee D Stem Cell Res Ther. 2021; 12(1):211.

PMID: 33766099 PMC: 7992329. DOI: 10.1186/s13287-021-02277-x.


A CRISPR Screen Reveals Resistance Mechanisms to CD3-Bispecific Antibody Therapy.

Liu S, Grantham A, Landry C, Granda B, Chopra R, Chakravarthy S Cancer Immunol Res. 2020; 9(1):34-49.

PMID: 33177106 PMC: 8601150. DOI: 10.1158/2326-6066.CIR-20-0080.


References
1.
Hrusak O, Porwit-Macdonald A . Antigen expression patterns reflecting genotype of acute leukemias. Leukemia. 2002; 16(7):1233-58. DOI: 10.1038/sj.leu.2402504. View

2.
Lillemeier B, Pfeiffer J, Surviladze Z, Wilson B, Davis M . Plasma membrane-associated proteins are clustered into islands attached to the cytoskeleton. Proc Natl Acad Sci U S A. 2006; 103(50):18992-7. PMC: 1681352. DOI: 10.1073/pnas.0609009103. View

3.
McCabe N, Gill H, Espinosa 3rd R, Patel Y, Harden A, Rubinelli P . Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci U S A. 1991; 88(23):10735-9. PMC: 53005. DOI: 10.1073/pnas.88.23.10735. View

4.
Lillemeier B, Mortelmaier M, Forstner M, Huppa J, Groves J, Davis M . TCR and Lat are expressed on separate protein islands on T cell membranes and concatenate during activation. Nat Immunol. 2009; 11(1):90-6. PMC: 3273422. DOI: 10.1038/ni.1832. View

5.
Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R . ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest. 2007; 117(8):2051-8. PMC: 1934579. DOI: 10.1172/JCI32278. View